Cargando…
The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476233/ https://www.ncbi.nlm.nih.gov/pubmed/32105176 http://dx.doi.org/10.18553/jmcp.2020.26.3.236 |
| _version_ | 1784790093144260608 |
|---|---|
| author | Synnott, Patricia G. Bloudek, Lisa M. Sharaf, Ravi Carlson, Josh J. Pearson, Steven D. |
| author_facet | Synnott, Patricia G. Bloudek, Lisa M. Sharaf, Ravi Carlson, Josh J. Pearson, Steven D. |
| author_sort | Synnott, Patricia G. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9476233 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94762332022-09-15 The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council Synnott, Patricia G. Bloudek, Lisa M. Sharaf, Ravi Carlson, Josh J. Pearson, Steven D. J Manag Care Spec Pharm Perspectives on Value Academy of Managed Care Pharmacy 2020-03 /pmc/articles/PMC9476233/ /pubmed/32105176 http://dx.doi.org/10.18553/jmcp.2020.26.3.236 Text en Copyright © 2020, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Perspectives on Value Synnott, Patricia G. Bloudek, Lisa M. Sharaf, Ravi Carlson, Josh J. Pearson, Steven D. The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title | The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_full | The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_fullStr | The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_full_unstemmed | The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_short | The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_sort | effectiveness and value of siponimod for secondary progressive multiple sclerosis: a summary from the institute for clinical and economic review’s midwest comparative effectiveness public advisory council |
| topic | Perspectives on Value |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476233/ https://www.ncbi.nlm.nih.gov/pubmed/32105176 http://dx.doi.org/10.18553/jmcp.2020.26.3.236 |
| work_keys_str_mv | AT synnottpatriciag theeffectivenessandvalueofsiponimodforsecondaryprogressivemultiplesclerosisasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT bloudeklisam theeffectivenessandvalueofsiponimodforsecondaryprogressivemultiplesclerosisasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT sharafravi theeffectivenessandvalueofsiponimodforsecondaryprogressivemultiplesclerosisasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT carlsonjoshj theeffectivenessandvalueofsiponimodforsecondaryprogressivemultiplesclerosisasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend theeffectivenessandvalueofsiponimodforsecondaryprogressivemultiplesclerosisasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT synnottpatriciag effectivenessandvalueofsiponimodforsecondaryprogressivemultiplesclerosisasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT bloudeklisam effectivenessandvalueofsiponimodforsecondaryprogressivemultiplesclerosisasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT sharafravi effectivenessandvalueofsiponimodforsecondaryprogressivemultiplesclerosisasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT carlsonjoshj effectivenessandvalueofsiponimodforsecondaryprogressivemultiplesclerosisasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend effectivenessandvalueofsiponimodforsecondaryprogressivemultiplesclerosisasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil |